Lv43
430 积分 2025-03-13 加入
Abstract PO3-05-10: Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study
20天前
已完结
Abstract PO3-05-10: Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multi-center, open-label, single-arm, phase II study
30天前
已完结
Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study
1个月前
已完结
Advancing treatment efficacy: combined therapy of eribulin, anlotinib, and camrelizumab in advanced or metastatic retroperitoneal liposarcoma
2个月前
已完结
Results of a Phase Ib Study Investigating Durvalumab in Combination with Eribulin in Patients with HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer
2个月前
已完结
Eribulin for patients with metastatic extramammary Paget disease: Study protocol for a single‐arm phase II trial
2个月前
已完结
69P Efficacy and safety of eribulin in liposarcoma and leiomyosarcoma: A systematic review and meta-analysis
2个月前
已完结
Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study
3个月前
已完结
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
3个月前
已完结
皖公网安备34019202002308
